期刊文献+

免疫细胞治疗肿瘤的安全性及其相应的对策初探 被引量:2

下载PDF
导出
摘要 传统肿瘤治疗手段(手术、化疗和放疗)在治疗肿瘤中发挥了积极的作用,但这些方法通常有一定的适应证和局限性,其副作用也是众所周知的,有时这些治疗手段甚至会加重肿瘤的进展。而最近成为癌症治疗热点的生物免疫治疗,本质上说是通过调整机体自身的免疫功能,从而达到抑制和杀灭肿瘤细胞的目的,副作用相对较小。目前的生物免疫治疗方法主要包括免疫检查点抑制和过继T细胞免疫治疗。
出处 《中国医药生物技术》 2016年第2期145-150,169,共7页 Chinese Medicinal Biotechnology
基金 国家自然科学基金(81301307 81272427 31471339)
  • 相关文献

参考文献81

  • 1Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 2002, 298(5594):850-854.
  • 2Ledford H. Melanoma drug wins US approval. Nature, 2011, 471 (7340):561.
  • 3Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death- receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet, 2014, 384(9948):1109-1117.
  • 4Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 2011,364(26):2517-2526.
  • 5Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-I antibody in cancer. N Engl J Med, 2012, 366(26):2443-2454.
  • 6Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 2015, 372(4):311-319.
  • 7Motzer R J, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol, 2015, 33(13):1430-1437.
  • 8Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014, 515(7528):558-562.
  • 9U. S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Ver. 4.03. 2009 (2010-06-14). http://evs.nci.nih. gov/ftpl/CTCAE/CTCAE 4.03 2010-06-14_QuickReference_5x7.pdf.
  • 10Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol, 2010, 11(2):155-164.

同被引文献32

引证文献2

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部